A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With Remibrutinib
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With Remibrutinib
The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).
The study is a randomized, open-label, non-inferiority multi-center, Phase 3b study to provide efficacy, safety, and tolerability data for remibrutinib after switching from ocrelizumab and in comparison to continuous ocrelizumab in plwRMS.
This study consists of an initial Core Part (CP) (maximum duration per participant of up to 24 months), followed by an Extension Part (EP) (of up to 24 months duration) for eligible participants.
All participants completing the 24-month treatment of the Core Part of the study may be eligible to continue in the Extension Part, an open-label, single-arm, fixed-dose design in which participants are treated with remibrutinib for up to 24 months.
The study will be conducted in the USA among other countries globally.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other inclusion and exclusion criteria may apply
novartis.email@novartis.com1-888-669-6682
+41613241111
Scottsdale, Arizona 85253, United States
aromero@prcresearcheducation.com
Washington D.C., District of Columbia 20010-2975, United States
Caba, C1182, Argentina
vero@hs.uci.edu
anu.r.bhooshan@medstar.net+1 202 877 8946
adiresearchcfl@gmail.com+1 407 790 4990
wjm1433@ufl.edu
hikhan@mhs.net+1 954 265 6934
admin@naparesearch.com+1 407 647 5996
rfernandez@eliteclinicalresearch.com+1 305 262 3396
taylor@aqualaneresearch.com+1 239 434 0332
mckinzie.mctyeire@adventhealth.com+1 407 303 5600
Charlene.carlo@orlandohealth.com+1 407 352 5434
sharondevore@hotmail.com+1 850 878 8121
amjackson@usf.edu+1 813 974 9423
cbergamino@geodysseyrsch.com+1 772 492 7051#232
Bartosz.Jacher@Northwestern.edu
cbibbs@bsd.uchicago.edu+1 773 702 5382
vwhitley@kumc.edu+1 913 588 9600
yemisrach.g.tadesse@medstar.net
Anish.Panda@lahey.org+1 781 744 3874
bcalitri@neurocenterne.com+1 781 551 5812
eblazejewski@mindonline.com+1 248 553 0010
skatt@memorialhealthcare.org
k.watson@wustl.edu+1 314 362 3293
keelenl@ccf.org+1 702 483 6003
dkramer@holyname.org
ejreese@salud.unm.edu+1 505 272 2836
kpatrick@buffalo.edu
HPatel@velocityclinical.com
destini.spaeth@sanfordhealth.org
djmchone@premierhealth.com
gyebign@ucmail.uc.edu+ 1 513 558 4489
maniawd@ccf.org+1 216 445 5788
Megan.Heckathorn@ohiohealth.com1 614 566 1262
hunter.weaver@providence.org+1 503 216 1150
jada.c@premier-neuro.com+1 864 655 4005
kpuccio@hopeneuro.com+1 865 218 6222
krodriguez@innovoresearch.com+1 512 344 0362
manuel.huichapa@utsouthwestern.edu
Vjovic@jpshealth.org
mfligg@saturnclinical.com+1 972 403 8184
aarati.pokharel@vcuhealth.org
Emily.barraza@cndmilwaukee.com
afreiberg@mcw.edu+1 414 805 5249